SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Array Biopharma, Inc
An SI Board Since March 2005
Posts SubjectMarks Bans Symbol
321 29 0 ARRY
Emcee:  keokalani'nui Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
171Who knew that 15-20% of the MC was in p53?? :-)scaram(o)uche-8/1/2012
170Clovis Oncology and Array BioPharma Announce Agreement to Discover Novel Mutant scaram(o)uche-7/17/2012
169Thanks for the pointer! Guess there's some good news in there too, rose-coloscaram(o)uche-7/9/2012
168AZN is testing its planned Phase 3 formulation of selumetinib, which appears to mcbio-7/7/2012
167OK, thanks. Need to listen presentation.Miljenko Zuanic-6/7/2012
166Squarer gave a great presentation (Jefferies), excepting the pretense around proscaram(o)uche16/7/2012
165What next he has in sleeves? Miljenko Zuanic-6/7/2012
164Real high-quality investors that Carruthers attracted for that last offering. Ascaram(o)uche-6/7/2012
163>> I like more 162 << As McBio pointed to, there's now a direcscaram(o)uche-6/5/2012
162Sure there can be multiple player in MEK "universe". I am bit trilled Miljenko Zuanic-6/5/2012
161That drug only works in BRAF melanoma. MEK162 has now shown activity in NRAS memcbio-6/4/2012
160Competitor: nejm.orgMiljenko Zuanic-6/4/2012
15937% vs. zero....... finance.yahoo.com Promising Data for KRAS Mutant Advancedscaram(o)uche-6/4/2012
158>> The efficacy of MEK inhibitors against B7-H1-mediated inhibition of CTLscaram(o)uche-5/30/2012
157fwiw..... Int J Oncol. 2012 May 23. doi: 10.3892/ijo.2012.1494. [Epub ahead ofscaram(o)uche-5/30/2012
156Piddly little market cap imo, in perspective.scaram(o)uche-5/16/2012
155Ah. Used "cholangiocarcinoma" as my search term and came up empty. Ttuck-4/23/2012
154Cool! clinicaltrials.gov >> Subset analysis? << Yes, and estimatscaram(o)uche-4/22/2012
153Selumetinib may promote muscle gain in cholangiocarcinoma pts (thanks to McBio ftuck-4/22/2012
152<i>"liquidity providers"</i> groan......scaram(o)uche-3/23/2012
151Nature. 2012 Mar 18. doi: 10.1038/nature10937. [Epub ahead of print] A murine scaram(o)uche13/21/2012
150>> I was not able to find any preclinical result that will pinpoint into rscaram(o)uche-3/2/2012
149I am not sure, didn't investigate this in details, but it seams that GenenteMiljenko Zuanic-2/29/2012
148>> so the partner’s best interest may not be what they expected << scaram(o)uche-2/29/2012
147This was comparison (not "add on") open study, so no true correlation Miljenko Zuanic-2/12/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News